Skip to main content
    T

    TriSalus Life Sciences Inc. (TLSI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.27
    -0.16 (-6.58%)

    Market Cap: $149.93M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    TriSalus Life Sciences Inc. (TLSI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    TriSalus Life Sciences reported revenue of $45.15M for the fiscal year ended Dec 31, 2025, up 53.4% from the year before. That year, net income was -$39.23M with a net margin of -86.9%, operating cash flow was -$18.01M and free cash flow was -$18.93M. The quarter ended Sep 30, 2026 had revenue of $12.88M and net income of -$8.85M.

    Revenue and Margins

    The operating margin was -59.7% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$45.15M+53.4%84.6%-59.7%-86.9%
    Dec 2024$29.43M+59.0%86.1%-122.9%-102.1%
    Dec 2023$18.51M+49.3%85.9%-294.3%-320.7%
    Dec 2022$12.40MN/A81.8%-293.9%-380.6%
    Dec 2021$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Revenue$45.15M$29.43M$18.51M$12.40M$0
    Cost of revenue$6.96M$4.10M$2.60M$2.26M$0
    Gross profit$38.19M$25.33M$15.91M$10.14M$0
    Research and development$14.96M$17.69M$29.84M$21.36M$0
    Operating income-$26.95M-$36.16M-$54.48M-$36.44M-$3.04M
    Net income-$39.23M-$30.05M-$59.36M-$47.19M$4.77M
    EBITDAN/A-$26.00MN/AN/A$4.70M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$12.88M$11.41M$8.90M$13.21M$11.57M$11.21M$9.17M$8.26M$7.35M$7.36M$6.46M$5.72M
    Gross profit$11.10M$9.90M$7.67M$11.44M$9.66M$9.41M$7.67M$7.04M$6.34M$6.45M$5.49M$5.14M
    Operating income-$7.71M-$9.81M-$8.41M-$3.27M-$9.01M-$7.33M-$7.33M-$7.58M-$8.74M-$8.17M-$11.67M-$14.30M
    Net income-$8.85M-$9.19M$1.54M-$9.75M-$10.81M-$8.29M-$10.38M-$10.11M-$2.40M-$4.33M-$13.21M-$35.70M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $33.21M exceeded cash and equivalents by $12.77M. Shareholder equity was negative, at -$33.86M, as total liabilities of $69.19M exceeded total assets of $35.33M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$35.33M$23.97M$24.60M$22.00M$250.53M$252.01M
    Current assets$32.24M$20.67M$20.86M$17.21M$525.88K$2.01M
    Cash and equivalents$20.44M$8.53M$11.78M$9.41M$200.88K$1.33M
    Total liabilities$69.19M$49.87M$51.66M$34.32M$17.25M$23.50M
    Short-term debt$167.00K$216.00K$351.00K$370.00K$544.00KN/A
    Long-term debt$33.05M$22.08M$0N/A$0N/A
    Shareholder equity-$33.86M-$25.89M-$27.07M-$176.33M-$16.72M-$21.48M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$57.56M$62.45M$70.98M$35.33M$36.46M$41.32M$28.63M$23.97M$27.48M$32.43M$17.89M$24.60M
    Total liabilities$56.88M$55.90M$58.17M$69.19M$63.19M$60.74M$62.99M$49.87M$47.91M$56.58M$52.81M$51.66M
    Cash and equivalents$41.06M$46.29M$56.55M$20.44M$22.69M$26.49M$13.00M$8.53M$11.29M$16.48M$3.97M$11.78M
    Shareholder equity$680.00K$6.55M$12.81M-$33.86M-$26.73M-$19.42M-$34.37M-$25.89M-$20.43M-$24.15M-$34.92M-$27.07M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$18.01M-$40.84M-$50.58M-$32.31M-$1.74M-$677.60K
    Capital expenditures$918.00K$345.00K$588.00K$655.00K$1.26M$545.00K
    Free cash flow-$18.93M-$41.19M-$51.17M-$32.97M-$3.00M-$1.22M
    Share repurchases$1.55M$0$20.00K$0$0N/A
    Investing cash flow-$838.00K-$345.00K-$1.59M-$1.79M$60.00KN/A
    Financing cash flow$30.76M$37.94M$54.63M$13.46M$544.00K$252.01M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.28M-$10.13M-$6.48M-$2.48M-$3.71M-$7.32M-$4.50M-$5.71M-$10.85M-$13.42M-$10.87M-$9.18M
    Capital expenditures$90.00K$82.00K$141.00K$41.00K$216.00K$93.00K$754.00K$50.00K$169.00K$60.00K$66.00K$372.00K
    Free cash flow-$5.37M-$10.21M-$6.62M-$2.52M-$3.92M-$7.41M-$5.25M-$5.76M-$11.02M-$13.48M-$10.93M-$9.55M
    Last 12 quarters

    Frequently Asked Questions About TLSI

    What is TriSalus Life Sciences' annual revenue?

    TriSalus Life Sciences reported revenue of $45.15M for the fiscal year ended Dec 31, 2025.

    How fast is TriSalus Life Sciences' revenue growing?

    Revenue was up 53.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 53.9%.

    Is TriSalus Life Sciences profitable?

    No. TriSalus Life Sciences reported net income of -$39.23M for the fiscal year ended Dec 31, 2025, with a net margin of -86.9%.

    How much free cash flow does TLSI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.01M minus capital expenditures of $918.00K produced free cash flow of -$18.93M.

    How much debt does TriSalus Life Sciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $33.05M, short-term debt of $167.00K and cash and equivalents of $20.44M.